Evidence map›Paper›PMID 34959608›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Tetrahydroimidazo[4,5-

Daniel Ramsbeck, Nadine Taudte, Nadine Jänckel, Stefanie Strich, Jens-Ulrich Rahfeld, Mirko Buchholz

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Novel small molecule targeting PgQC reducesFrontiers in oral health · 2026
    Article
  2. Synthesis of Fused spChemistryOpen · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel RamsbeckFraunhofer Institute for Cell Therapy and Immunology IZI, Department of Drug Design and Target Validation MWT, Weinbergweg 22, 06120 Halle (Saale), Germany.ORCID 0000-0002-4966-142X
Nadine TaudtePerioTrap Pharmaceuticals GmbH, Weinbergweg 22, 06120 Halle (Saale), Germany.
Nadine JänckelPerioTrap Pharmaceuticals GmbH, Weinbergweg 22, 06120 Halle (Saale), Germany.
Stefanie StrichFraunhofer Institute for Cell Therapy and Immunology IZI, Department of Drug Design and Target Validation MWT, Weinbergweg 22, 06120 Halle (Saale), Germany.
Jens-Ulrich RahfeldFraunhofer Institute for Cell Therapy and Immunology IZI, Department of Drug Design and Target Validation MWT, Weinbergweg 22, 06120 Halle (Saale), Germany.ORCID 0000-0002-8979-581X
Mirko BuchholzPerioTrap Pharmaceuticals GmbH, Weinbergweg 22, 06120 Halle (Saale), Germany.ORCID 0000-0002-2629-4153
Fraunhofer Institute for Cell Therapy and Immunology · DE

Funding

European Union 306029
6 · The paper itself

Abstract

Periodontitis is a severe yet underestimated oral disease. Since it is linked to several systemic diseases, such as diabetes, artheriosclerosis, and even Alzheimer's disease, growing interest in treating periodontitis has emerged recently. The major cause of periodontitis is a shift in the oral microbiome. A keystone pathogen that is associated with this shift is

Indexed as

glutaminyl cyclaseperiodontitisPgQCPorphyromonas gingivalis

Identifiers

PMID34959608
PMCPMC8709289
OpenAlexW3216857892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.